SAGE PRO

Home / Research / Sammaan Capital Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Sammaan Capital Limited — Q2 FY27 Results Analysis

WATCH

Published · Quarter Q2 FY27 · SAMMAANCAP

Operating or earnings figure₹59,188 crore AUM
Credit or earnings checkpoint₹312 crore PAT
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

AUM

Q2 FY26₹64,004 crore
Q1 FY27₹56,239 crore
Q2 FY27₹59,188 crore
CHART 2

Disbursements

Q1 FY27₹3,875 crore
Q2 FY27₹6,278 crore
CHART 3

PAT

Q1 FY27₹243 crore
Q2 FY27₹312 crore
CHART 4

PBT

Q1 FY27₹326 crore
Q2 FY27₹425 crore
ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

WATCH

Sammaan’s sequential turnaround needs a bridge from recoveries and capital infusion to repeatable earnings per diluted share.

Watch: Base monitoring is tied to cohort economics and funding, with company guidance treated as a benchmark. Upside requires the growth book to contribute more profit after credit costs and overhead as legacy recoveries decline. The downside is…

RESEARCH INSIGHT

Earnings and growth

Reported quarterly PBT climbed from ₹326 crore to ₹425 crore. Management reported net recoveries of ₹217 crore versus ₹240 crore in June. Net recoveries were about 51% of current PBT as a scale comparison. The net recovery definition mixes recoveries, incremental provisions and other credit costs, so subtracting it mechanically would give an unreliable normalized earnings number.

Watch: Base monitoring is tied to cohort economics and funding, with company guidance treated as a benchmark. Upside requires the growth book to contribute more profit after credit costs and overhead as legacy recoveries decline. The downside is…

RESEARCH INSIGHT

Earnings and growth

Reported quarterly PBT climbed from ₹326 crore to ₹425 crore. Management reported net recoveries of ₹217 crore versus ₹240 crore in June. Net recoveries were about 51% of current PBT as a scale comparison. The net recovery definition mixes recoveries, incremental provisions and other credit costs, so subtracting it mechanically would give an unreliable normalized earnings number.

Watch: Base monitoring is tied to cohort economics and funding, with company guidance treated as a benchmark. Upside requires the growth book to contribute more profit after credit costs and overhead as legacy recoveries decline. The downside is…

RESEARCH INSIGHT

Operating performance

Disbursements climbed from ₹3,875 crore to ₹6,278 crore while the branch network increased from 217 to 245. Management is building personal-loan origination and adding gold and MSME products. Product growth must be tracked separately because funding needs, expected losses, servicing expenses and capital intensity differ from those of the mortgage portfolio.

Watch: Base monitoring is tied to cohort economics and funding, with company guidance treated as a benchmark. Upside requires the growth book to contribute more profit after credit costs and overhead as legacy recoveries decline. The downside is…

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Sage PRO · SAMMAANCAP · Quarter ended 30 September 2026 · 18 November 2026

Stance: Watch. Sammaan’s sequential turnaround needs a bridge from recoveries and capital infusion to repeatable earnings per diluted share.

Opening dashboardReported result
Key operating or earnings figure₹59,188 crore AUM
Credit or earnings checkpoint₹312 crore PAT

1. Investment decision

Key takeaways

  • September AUM rose 5% sequentially to ₹59,188 crore and PAT rose 28% to ₹312 crore.
  • AUM remained about 7.5% below the ₹64,004 crore reported a year earlier.
  • That combination is consistent with a recovery from the June base while the earlier loan book continues to run off.

Treat Sammaan as a diversified mortgage-led NBFC for peer work. The FY25 annual report records the transition to an RBI NBFC–Investment and Credit Company registration.

AUM (₹ crore)

Q2 FY26Q1 FY27Q2 FY27
64,00456,23959,188

Disbursements (₹ crore)

Q1 FY27Q2 FY27
3,8756,278

2. Financial quality

Key takeaways

  • Reported quarterly PBT climbed from ₹326 crore to ₹425 crore.
  • Management reported net recoveries of ₹217 crore versus ₹240 crore in June.
  • Net recoveries were about 51% of current PBT as a scale comparison.

The net recovery definition mixes recoveries, incremental provisions and other credit costs, so subtracting it mechanically would give an unreliable normalized earnings number.

PAT (₹ crore)

Q1 FY27Q2 FY27
243312

PBT (₹ crore)

Q1 FY27Q2 FY27
326425

3. Business and origination

Key takeaways

  • Disbursements climbed from ₹3,875 crore to ₹6,278 crore while the branch network increased from 217 to 245.
  • Management is building personal-loan origination and adding gold and MSME products.
  • Product growth must be tracked separately because funding needs, expected losses, servicing expenses and capital intensity differ from those of the mortgage portfolio.

Net recoveries (₹ crore)

Q1 FY27Q2 FY27
240217

GNPA (%)

Q1 FY27Q2 FY27
0.210.15

4. Credit risk

Key takeaways

  • Reported GNPA eased to 0.15% from 0.21% and NNPA to 0.11% from 0.15% sequentially.
  • The issuer also reports performance on sold-down mortgage pools.
  • Assess managed and on-balance-sheet credit performance independently, especially after assignment and when assessing the new personal and MSME loan vintages.

NNPA (%)

Q1 FY27Q2 FY27
0.150.11

Net worth before October infusion (₹ crore)

Q1 FY27Q2 FY27
19,12919,445

5. Funding and capital

Key takeaways

  • September net worth was ₹19,445 crore and capital adequacy 20.0%.
  • The ₹906 crore first-tranche warrant proceeds arrived on 30 October after the quarter close.
  • They should enter a pro forma capital bridge along with the 8.69 crore shares issued.

Remaining warrant conversion is conditional. Using the higher cash amount with a September share count would overstate book value per share.

Branch network (branches)

Q1 FY27Q2 FY27
217245

Disbursements required by full-year guidance (₹ crore)

H1 actualH2 implied
10,15319,947

6. Peers and valuation

Key takeaways

  • Management’s full-year targets imply ₹19,947 crore of H2 disbursements and ₹844 crore of H2 PAT against reported H1 totals of ₹10,153 crore and ₹556 crore.
  • The implied H2 disbursement run rate is almost twice the H1 pace.
  • Use that bridge to track execution, with a separate check on customer mix and credit quality if origination accelerates.

The 17 November market reference was ₹131.29. A comparable price-to-book valuation requires common equity, period-end ordinary shares and a separate dilution bridge where applicable. An exact target is withheld pending verification of those inputs and consistent peer multiples.

7. Scenarios and monitoring

Key takeaways

  • Base monitoring is tied to cohort economics and funding, with company guidance treated as a benchmark.
  • Upside requires the growth book to contribute more profit after credit costs and overhead as legacy recoveries decline.
  • The downside is volume growth with weaker collections or dilution faster than normalized earnings growth.

Reconcile actual share issuance and the asset and liability maturity ladder before a per-share valuation.

CaseOperating assumptions
BearSlower recoveries and higher credit or acquisition costs overwhelm growth in new originations.
BaseDisbursements grow, while legacy and growth profitability remain separately tracked and warrant dilution is recognized.
BullRecurring profit from newer vintages offsets declining recoveries and improves earnings per diluted share.

Sensitivity. An annualized 25 basis point change applied to the reported closing AUM is equivalent to approximately ₹148.0 crore before tax. This isolates scale. Realized effects depend on average on-balance-sheet assets, assigned balances, repricing, funding and the timing of income or provisions.

Evidence and limitations

Key takeaways

  • The analysis uses results and disclosures for the September 2026 quarter.
  • Ratios and financial balances use the issuer’s definitions.
  • Figures rounded by the issuer can produce small differences when percentage changes are recalculated.

Scenario assumptions represent operating outcomes. Comparable diluted peer valuation, granular maturity buckets and loan-cohort performance remain diligence items. Market price is an observation from 17 November.

- - - -

Q2 source and financial review · 18 November 2026

Key takeaways

  • Management described access to global funding through its strategic shareholder as a priority on the November 14 call.
  • Count any benefit only when executed borrowing terms, maturities and hedged costs are disclosed.
  • Track cost of funds alongside the new product losses and actual warrant conversions before underwriting returns per share.

Additional earnings and capital analysis

Key takeaways

  • The FY27 targets imply an average H2 quarter of about ₹9,974 crore in disbursements and ₹422 crore in PAT.
  • Those are about 59% and 35% above the reported September quarter respectively.
  • This comparison identifies the acceleration embedded in guidance without treating it as the base case.

The earnings deck also distinguishes ₹59,188 crore of managed AUM from a ₹46,482 crore loan book. The difference is not a complete measure of transferred risk because structured retention and servicing terms matter. A 50-bp annualized funding or credit-cost shock applied illustratively to the closing loan book is about ₹232 crore before tax. That is a scale comparison only, since funding costs apply to liabilities, credit charges apply to eligible exposures, and balances vary during the year.

For valuation, reconcile quarter-end ordinary shares with the dated warrant conversions, the use of proceeds and cash actually available to the parent. Gains on sale, fee income and net recovery effects should be isolated from the underlying spread and operating expense bridge before extrapolating PAT.

Additional company evidence

CHART 5

Net recoveries

Q1 FY27₹240 crore
Q2 FY27₹217 crore
CHART 6

GNPA

Q1 FY270.21%
Q2 FY270.15%
CHART 7

NNPA

Q1 FY270.15%
Q2 FY270.11%
CHART 8

Net worth before October infusion

Q1 FY27₹19,129 crore
Q2 FY27₹19,445 crore
SOURCE REFERENCES

Original disclosures and investor presentations

Original references are in the published manuscript below.

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.